Tags

Type your tag names separated by a space and hit enter

Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Arthritis Res Ther. 2005; 7(2):R333-42.AR

Abstract

This pharmacoepidemiologic study was conducted to determine whether risk factors for upper gastrointestinal bleeding influenced the prescription of cyclo-oxygenase (COX)-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) at the time when COX-2 inhibitors were first included in the formulary of reimbursed medications. A population-based case-control study was conducted in which the prevalence of risk factors and the medical histories of patients prescribed COX-2 inhibitors and traditional nonselective NSAIDs were compared. The study population consisted of a random sample of members of the Quebec drug plan (age 18 years or older) who received at least one dispensation of celecoxib (n = 42,422; cases), rofecoxib (n = 25,674; cases), or traditional nonselective NSAIDs (n = 12,418; controls) during the year 2000. All study data were obtained from the Quebec health care databases. Adjusting for income level, Chronic Disease Score, prior use of low-dose acetylsalicylic acid, acetaminophen, antidepressants, benzodiazepines, prescriber specialty, and time period, the following factors were significantly associated with the prescription of COX-2 inhibitors: age 75 years or older (odds ratio [OR] 4.22, 95% confidence interval [CI] 3.95-4.51), age 55-74 years (OR 3.23, 95% CI 3.06-3.40), female sex (OR 1.52, 95% CI 1.45-1.58), prior diagnosis of gastropathy (OR 1.21, 95% CI 1.08-1.36) and prior dispensation of gastroprotective agents (OR 1.57, 95% CI 1.47-1.67). Patients who received a traditional nonselective NSAID recently were more likely to switch to a coxib, especially first-time users (OR 2.17, 95% CI 1.93-2.43). Associations were significantly greater for celecoxib than rofecoxib for age, chronic NSAID use, and last NSAID use between 1 and 3 months before the index date. At the time of introduction of COX-2 inhibitors into the formulary, prescription channeling could confound risk comparisons across products.

Authors+Show Affiliations

Faculty of Pharmacy, Université de Montréal, Montreal, Canada. yola.moride@umontreal.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15743481

Citation

Moride, Yola, et al. "Prescription Channeling of COX-2 Inhibitors and Traditional Nonselective Nonsteroidal Anti-inflammatory Drugs: a Population-based Case-control Study." Arthritis Research & Therapy, vol. 7, no. 2, 2005, pp. R333-42.
Moride Y, Ducruet T, Boivin JF, et al. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther. 2005;7(2):R333-42.
Moride, Y., Ducruet, T., Boivin, J. F., Moore, N., Perreault, S., & Zhao, S. (2005). Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Research & Therapy, 7(2), R333-42.
Moride Y, et al. Prescription Channeling of COX-2 Inhibitors and Traditional Nonselective Nonsteroidal Anti-inflammatory Drugs: a Population-based Case-control Study. Arthritis Res Ther. 2005;7(2):R333-42. PubMed PMID: 15743481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. AU - Moride,Yola, AU - Ducruet,Thierry, AU - Boivin,Jean-François, AU - Moore,Nicholas, AU - Perreault,Sylvie, AU - Zhao,Sean, Y1 - 2005/01/17/ PY - 2004/07/08/received PY - 2004/11/09/revised PY - 2004/12/01/accepted PY - 2005/3/4/pubmed PY - 2005/12/16/medline PY - 2005/3/4/entrez SP - R333 EP - 42 JF - Arthritis research & therapy JO - Arthritis Res Ther VL - 7 IS - 2 N2 - This pharmacoepidemiologic study was conducted to determine whether risk factors for upper gastrointestinal bleeding influenced the prescription of cyclo-oxygenase (COX)-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) at the time when COX-2 inhibitors were first included in the formulary of reimbursed medications. A population-based case-control study was conducted in which the prevalence of risk factors and the medical histories of patients prescribed COX-2 inhibitors and traditional nonselective NSAIDs were compared. The study population consisted of a random sample of members of the Quebec drug plan (age 18 years or older) who received at least one dispensation of celecoxib (n = 42,422; cases), rofecoxib (n = 25,674; cases), or traditional nonselective NSAIDs (n = 12,418; controls) during the year 2000. All study data were obtained from the Quebec health care databases. Adjusting for income level, Chronic Disease Score, prior use of low-dose acetylsalicylic acid, acetaminophen, antidepressants, benzodiazepines, prescriber specialty, and time period, the following factors were significantly associated with the prescription of COX-2 inhibitors: age 75 years or older (odds ratio [OR] 4.22, 95% confidence interval [CI] 3.95-4.51), age 55-74 years (OR 3.23, 95% CI 3.06-3.40), female sex (OR 1.52, 95% CI 1.45-1.58), prior diagnosis of gastropathy (OR 1.21, 95% CI 1.08-1.36) and prior dispensation of gastroprotective agents (OR 1.57, 95% CI 1.47-1.67). Patients who received a traditional nonselective NSAID recently were more likely to switch to a coxib, especially first-time users (OR 2.17, 95% CI 1.93-2.43). Associations were significantly greater for celecoxib than rofecoxib for age, chronic NSAID use, and last NSAID use between 1 and 3 months before the index date. At the time of introduction of COX-2 inhibitors into the formulary, prescription channeling could confound risk comparisons across products. SN - 1478-6362 UR - https://www.unboundmedicine.com/medline/citation/15743481/Prescription_channeling_of_COX_2_inhibitors_and_traditional_nonselective_nonsteroidal_anti_inflammatory_drugs:_a_population_based_case_control_study_ L2 - https://arthritis-research.biomedcentral.com/articles/10.1186/ar1488 DB - PRIME DP - Unbound Medicine ER -